Onward Medical N : ONWD – Company Presentation (January 2023)

Company Deck

January 2023

Forward Looking Statements

This Presentation may include statements, including the Company's financial and operational medium- term objectives, that may be deemed to be ''forward-looking statements''. These forward-looking statements may be identified by the use of forward-looking terminology, including the terms '' believes''," aims"," forecasts"," continues",'' estimates'','' plans'','' projects'','' anticipates'','' expects'','' intends'','' may'','' or '' or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Forward-looking statements may and often do differ materially from actual results. Any forward-looking statements reflect the Company's current view concerning future events and are subject to risks relating to future events and other risks, uncertainties, and assumptions relating to the Company's business, results of operations, financial position, liquidity, prospects, growth, or strategies. Forward-looking statements speak only as of the date they are made.

ONWARD Company Deck

2

Key Facts

1. Founded in 2015

1. 100+ FTEs1

1. HQ in Eindhoven, the Netherlands

1. Science and Engineering Center in Lausanne, Switzerland

1. Growing US presence centered in Boston, Massachusetts

1. IPO 2021, Euronext Brussels and Amsterdam; $150M+ raised since inception

1 As of 01 December 2022

ONWARD at a Glance

Technology - 2 purpose-built neuromodulation platforms that stimulate the spinal cord via implantable (ARCIM) or external (ARCEX) technologies

Innovation - 5+ FDA Breakthrough Device Designations and 330+ issued or pending patents

Clinical Validation - One pivotal trial complete with positive top line results reported for ARCEX; positive interim outcomes also reported for ARCIM blood pressure indication

Commercialization - Large Total Available Market ($20B+); first commercial sale expected in H2 2023; favorable reimbursement for ARCIM in the US; strategic relationship with Christopher Reeve Foundation

ONWARD Company Deck

3

Large unmet need:

There is no cure for spinal cord injury (SCI)

Devastating	Prevalent
Not only paralysis & loss of	US & Europe1,2
sensation; frequently also	Prevalence ~650,000
infection, incontinence, loss of	Incidence ~50,000
sexual function, and other
challenges	Global2
	Prevalence ~7,000,000
Assistance required to support	Incidence ~768,000
activities of daily life
Quality of life can be poor

1. NSCISC Annual Report, US and Europe only - with 25 years old patients, World Health Organization Fact Sheet, November 2013, estimate 40-80 cases per million.
2. Kumar et al. 2018, Traumatic Spinal Injury: Global Epidemiology and Worldwide Volume - Traumatic spinal injury may be broader than traumatic spinal cord injury.

Problem

Costly

Avg Lifetime Cost (paraplegic)

$2.5M

Avg Lifetime Cost (tetraplegic)

$5.0M

ONWARD Company Deck

4

Vision

Empowered by movement, people with spinal cord injury will enjoy life in every way that matters to them

Confidentiall

ONWARD Company Deck

5